Company intelligence / Profile preview

Mega Genomics

Beijing, Beijing, Chinamegasoftware.net ↗

Ownership: Private
Employees: ~229
Development stage: Commercial

Overview

Mega Genomics is China’s largest consumer-grade genetic testing platform by cumulative number of tests performed through end of 2023 (>19 million). It offers a broad portfolio covering cancer screening and chronic disease risk assessment using advanced high-throughput technology. The company collaborates with over 1,800 healthcare institutions across more than 340 cities in China and has strategic partnerships with e-commerce and online health platforms to expand access to its services

Therapeutic areas: OncologyCardiovascularNeurology
Modalities: Diagnostic testGenetic testing kit
Industry: Molecular Diagnostics

Partnerships

Over 1,800 healthcare institutions in >340 Chinese citiesStrategic cooperation with e-commerce and online healthcare platforms

Beyond the preview

Go deeper on Mega Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mega Genomics.

Explore the full profile